Filing Flows › 8-K events › BrightSpire Capital
BrightSpire Capital: entry into a material definitive agreement
Form 8-K filed Oct 21, 2026 · items 1.01, 2.03, 8.01
What the filing says
On October 16, 2026 (the “CLO Closing Date”), BrightSpire Capital, Inc. (the “Company”) entered into a collateralized loan obligation (the “CLO”) through its subsidiary real estate investment trust, BrightSpire Capital Mortgage Sub-REIT, LLC (“Sub-REIT”), and two wholly-owned subsidiaries of Sub-REIT, BRSP 2026-FL4 Ltd
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Item 8.01: +0.1% next session across 44,881. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.
BrightSpire Capital at a glance
BrightSpire Capital, Q3 2026: revenue $87.4M (+4% year over year), operating margin 28.4%. The chart follows the revenue to costs, profit and cash.
BrightSpire Capital: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent debt and financing
- Airsculpt Technologies Nov 6, 2026
- Starry Sea Acquisition Nov 6, 2026
- Repligen Nov 6, 2026
- Evertec Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Reed's Nov 6, 2026
- Protagenic Therapeutics, Inc.\new Nov 6, 2026
- CNL Strategic Residential Credit Nov 6, 2026
- Health In Tech Nov 6, 2026
- Profusa Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.